<!doctype html>
<html lang="en">
  <head>
    <meta charset="utf-8" />
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <title>Novo Nordisk Shares Rise as Obesity Trial Results Narrow Gap With Eli Lilly</title>
    <meta name="description" content="Sep 15 - Novo Nordisk (NYSE:NVO) reported that a higher semaglutide dose helped patients lose more weight in two late-stage trials, and its Copenhagen-listed shares rose about 1.5%.; The trials tested a 7.2 mg dose, three times the approved 2.4 mg, and measured weight change over 72 weeks.; Eli Lilly (NYSE:LLY) posted stronger headline results with tirzepatide, achieving up to 22.5 percent weight loss at its top dose, keeping competition tight.Observers said the incremental gains for semaglutide matter, esp" />
    <link rel="alternate" type="application/rss+xml" title="Daily Finance Newsletter" href="https://suavir600.github.io/newsletter/feed.xml" />
    <style>
:root{--bg:#0b0f19;--fg:#e8ecf2;--muted:#93a1b1;--card:#121826;--accent:#4f8cff}
*{box-sizing:border-box} body{margin:0;background:var(--bg);color:var(--fg);font:16px/1.55 system-ui,-apple-system,Segoe UI,Roboto,Ubuntu}
a{color:var(--accent);text-decoration:none} a:hover{text-decoration:underline}
.container{max-width:980px;margin:0 auto;padding:20px}
.nav{display:flex;align-items:center;justify-content:space-between;margin-bottom:20px}
.brand{font-weight:700} .muted{color:var(--muted)}
.grid{display:grid;grid-template-columns:repeat(auto-fill,minmax(280px,1fr));gap:16px}
.card{background:var(--card);border-radius:16px;padding:16px;box-shadow:0 6px 20px rgba(0,0,0,.25)}
.card h3{margin:0 0 8px 0;font-size:1.05rem}
.badge{display:inline-block;background:#1c2335;color:#c0cad8;padding:.2rem .5rem;border-radius:999px;font-size:.75rem;margin-right:.4rem}
.btn{display:inline-block;background:var(--accent);color:#fff;padding:.5rem .75rem;border-radius:10px;font-weight:600}
.btn-outline{background:transparent;border:1px solid var(--accent);color:var(--accent)}
.list ul{margin:.5rem 0 0 1.2rem}
.footer{margin-top:36px;color:var(--muted);font-size:.9rem;text-align:center}
hr{border:none;border-top:1px solid #223; margin:16px 0}
</style>
  </head>
  <body>
    <div class="container">
      <div class="nav">
        <div class="brand"><a href="https://suavir600.github.io/newsletter">Daily Finance Newsletter</a></div>
        <div class="muted">5–7 key bullets per story</div>
      </div>
      
<h1>Novo Nordisk Shares Rise as Obesity Trial Results Narrow Gap With Eli Lilly</h1>
<div class="muted">2025-09-15 12:44:22+00:00</div>
<hr />
<div class="list"><ul>
  <li>Sep 15 - Novo Nordisk (NYSE:NVO) reported that a higher semaglutide dose helped patients lose more weight in two late-stage trials, and its Copenhagen-listed shares rose about 1.5%.</li><li>The trials tested a 7.2 mg dose, three times the approved 2.4 mg, and measured weight change over 72 weeks.</li><li>Eli Lilly (NYSE:LLY) posted stronger headline results with tirzepatide, achieving up to 22.5 percent weight loss at its top dose, keeping competition tight.Observers said the incremental gains for semaglutide matter, esp</li><li>This article first appeared on GuruFocus.</li><li>In the larger study, participants on 7.2 mg lost an average of 19 percent of body weight, compared with about 16 percent on 2.4 mg and 4 percent on placebo.</li><li>Novo has faced setbacks in the U.S., including market share losses and a roughly 60 percent share decline over the past year as it trims its global workforce.</li><li>The data may strengthen Novo&#x27;s case for higher-dose strategies if regulators and payers accept the approach.</li>
</ul></div>
<div style="margin-top:12px">
  <a class="btn-outline" href="https://finance.yahoo.com/news/novo-nordisk-shares-rise-obesity-124422607.html" target="_blank" rel="noopener">Original</a>
  <a class="btn" href="https://twitter.com/intent/tweet?text=Novo+Nordisk+Shares+Rise+as+Obesity+Trial+Results+Narrow+Gap+With+Eli+Lilly%0A%E2%80%A2+Sep+15+-+Novo+Nordisk+%28NYSE%3ANVO%29+reported+that+a+higher+semaglutide+dose+helped+patients+lose+more+weight+in+two+late-stage+trials%2C+and+its+Copenhagen-listed+shares+rose+about+%E2%80%A6%0Ahttps%3A%2F%2Fsuavir600.github.io%2Fnewsletter%2Farticles%2Fnovo-nordisk-shares-rise-as-obesity-trial-results-narrow-gap-with-eli-lilly%2F" target="_blank" rel="noopener">Share on X</a>
</div>

      <div class="footer">© 2025 · Built from digest_5bullets.md</div>
    </div>
  </body>
</html>